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Abstract
IL-1α and IL-1β were evaluated for their ability to provide adjuvant activity for the induction of
serum antibody responses when nasally-administered with protein antigens in mice and rabbits. In
mice, intranasal (i.n.) immunization with pneumococcal surface protein A (PspA) or tetanus
toxoid (TT) combined with IL-1β induced protective immunity that was equivalent to that induced
by parenteral immunization. Nasal immunization of awake (i.e., not anesthetized) rabbits with
IL-1-adjuvanted vaccines induced highly variable serum antibody responses and was not as
effective as parenteral immunization for the induction of antigen-specific serum IgG. However,
i.n. immunization of deeply anesthetized rabbits with rPA + IL-1α consistently induced rPA-
specific serum IgG ELISA titers that were not significantly different than those induced by
intramuscular (IM) immunization with rPA + alum although lethal toxin neutralizing titers
induced by nasal immunization were lower than those induced by IM immunization. Gamma
scintigraphy demonstrated that the enhanced immunogenicity of nasal immunization in
anesthetized rabbits correlated with an increased nasal retention of i.n. delivered non-permeable
radio-labeled colloidal particles. Our results demonstrate that, in mice, IL-1 is an effective
adjuvant for nasally-administered vaccines for the induction of protective systemic immunity and
that in non-rodent species, effective induction of systemic immunity with nasally-administered
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vaccines may require formulations that ensure adequate retention of the vaccine within the nasal
cavity.
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INTRODUCTION
There is a growing interest in needle-free, non-invasive methods of vaccination, especially
in developing countries, since the re-use of consumable non-sterile supplies is often
responsible for transmission of infectious agents [1–6]. One modality for immunization that
is needle-free is nasal (mucosal) immunization. The development of safe and effective nasal
immunization regimens would provide a relatively non-invasive approach for vaccination
that may be useful for mass vaccination campaigns [1,4,7–9] as well as for use in people
who desire an alternative to injected vaccines due to fear of needles [10–14]. The FDA
approval and efficacy of the nasally-administered influenza vaccine Flumist (an
unadjuvanted, attenuated replicating virus) [15–17], demonstrates that nasal immunization
has the potential to be safe and effective for use in humans. The ability to induce both
systemic and mucosal immunity (i.e., S-IgA) is a benefit of mucosal immunization[18,19].
However, even if mucosal immunity is not required to protect the host against the pathogen
of interest, nasal immunization should be considered as a non-invasive method of
immunization that provides an alternative to delivery of vaccines via a needle injection.
When non-replicating antigens (proteins, peptides, polysaccharides) are used for nasal
immunization, adjuvants must be used to maximize the induction of antigen-specific
immune responses since nasal immunization in the absence of adjuvant may not induce the
desired immune response and may induce antigen-specific tolerance [20–24]. The balance
between the induction of tolerance and adjuvant-induced immunity is thought to be
associated with the ability of adjuvants to prevent the induction of regulatory T cells (T
regs[25]) secondary to adjuvant-dependent enhanced antigen uptake by dendritic cells (DC),
altered DC migration and enhanced DC co-stimulatory activity [26–29]. Although cholera
toxin (CTx) and related toxins have been used as mucosal vaccine adjuvants, the list of
observed adverse effects (induction of IgE, lethal anaphylaxis, pulmonary inflammation,
diarrhea, accumulation in olfactory tissues and Bell’s Palsy[30–36]) associated with their
use as mucosal vaccine adjuvants will likely prevent their use in humans. To identify non-
toxin nasal vaccine adjuvants, we evaluated recombinant cytokines for their ability to
provide adjuvant activity comparable to that provided by CTx. Our previous studies in mice
demonstrated that interleukin-1-alpha (IL-1α) and beta (IL-1β) provided adjuvant activity
when nasally administered with protein antigens and induced both antigen-specific serum
IgG and mucosal IgA comparable to that induced by CTx [37,38].
Effective nasal immunization in mice models may not translate into efficient immunization
in humans, or other animal species with an upper respiratory tract anatomy similar to
humans. Unlike rodents which have organized nasal-associated lymphoid tissue (NALT) in
the floor of the nasal cavity [39–43], the nasal inductive (NALT-like) tissues in larger
animals such as rabbits, non-human primates and humans, likely include tonsils, adenoids
and Waldeyer’s ring[44,45] which anatomically are less accessible to nasally-delivered
antigen/adjuvant compared to NALT in rodents. Indeed, we have previously demonstrated in
mice that the nasal route of immunization was able to induce serum IgG comparable to that
induced by an injected vaccine [46]. However, our past experience with nasal immunization
of non-human primates demonstrated that although nasal immunization (antigen + adjuvant)
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was able to induce statistically increased serum IgG responses, the antibody responses
induced by adjuvanted nasal immunization were approximately 10-fold lower than those
induced by adjuvanted intramuscular immunization [47]. Accordingly, for non-rodent
species, more research is needed to optimize nasal immunization regimens in non-rodent
species to achieve and maximize the induction of antigen-specific immunity, in both the
systemic and mucosal compartments.
The use of anesthesia with nasal immunization has been reported to augment antigen-
specific immune responses in mice, including anti-anthrax protective antigen (PA) antibody
responses as well as anthrax lethal toxin neutralizing activity [48,49]. The anesthetic agents
that augmented the vaccine-induced immune responses were agents such as propofol and
pentobarbital and were delivered by needle injection. The ability of the anesthetics to
increase the efficacy of nasal immunization may be attributed to an increased delivery of
vaccine to the lower respiratory tract[50] and/or delayed mucociliary clearance due to
decreased epithelial ciliary beat frequency [51]. Although the use of injectable anesthetics
with nasal immunization regimens applied to humans is not realistic since it would negate
our goal of developing needle-free methods of vaccines, the use of anesthetics with
laboratory animals is needed to allow safe animal handling and effective vaccine delivery.
Therefore, anesthetized laboratory models will continue to be used in nasal immunization
studies and it is uncertain whether the use of anesthesia influences the efficacy of nasal
immunization in larger research animals (rabbits, non-human primates). A clearer
understanding of technical issues that influence the efficiency of nasal immunization in
larger non-rodent species will provide valuable insight to guide the fruitful development of
effective nasally-administered vaccines for use in humans.
In the present study we evaluated the ability of IL-1, when used as a nasal vaccine adjuvant
in mice, to induce protection against a systemic lethal challenge with Streptococcus
pneumoniae and tetanus toxin. In addition, we assessed the adjuvant activity of IL-1 by the
nasal immunization route in a rabbit model and monitored core body temperature as an
index of pyrogenicity. For this rabbit model, systemic anesthesia was also investigated to
evaluate its influence upon efficacy of nasal immunization adjuvanted with IL-1.
MATERIALS AND METHODS
Animals
Female BALB/c mice, 16–18 grams, were purchased from Charles River. Female New
Zealand White (NZW) rabbits, 2.5–3 kg, were purchased from Robinson Services
(Mocksville, NC). Animals were housed in cages and provided food and water ad libitum.
Mice were housed in groups of 5 mice per cage (all mice within a cage received the same
vaccine) and rabbits were housed individually. Procedures for use and care of animals were
approved by Duke University’s Institutional Animal Care and Use Committee.
Reagents
Recombinant protective antigen (rPA), recombinant lethal factor (rLF), cholera toxin (CT)
and tetanus toxin were purchased from List Biologicals (Campbell, CA). rPA and rLF were
also obtained from BEI Resources. PspA protein was graciously obtained from Dr. Gary
Nabors, Aventis, Lot # 589A-11, Rx1M1 PspA. Imject Alum was obtained from PIERCE
(Cat # 77160; aluminum hydroxide). Tetanus toxoid was a kind gift from Pasteur Merrieux
Connaught. ISA-51[52–54] was obtained from Seppic (Fairfield, NJ) and was used to make
water in oil emulsion vaccines. We have previously reported that both murine IL-1α and
IL-1β exhibit nasal adjuvant activity[37]. Recombinant human (rhu) IL-1α was purchased
from R&D Systems (Minneapolis, MN) and rhuIL-1β was provided by CISTRON
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Biotechnology (Pine Brook, NJ). Others have demonstrated that human IL-1α and IL-1β
exhibit biological activity across species barriers [55–58] and that recombinant human IL-1α
exhibits mucosal adjuvant activity in rabbits[59]. Therefore, to allow these preclinical
studies to utilize the form of IL-1α or IL-1β that may be used in human studies, rhuIL-1α or
rhuIL-1β was used in our murine and rabbit studies. Sterile and non-pyrogenic
technetium-99m (Tc99m) was acquired from Duke University radio-pharmacy and added to
sodium thiosulfate according to the manufacturer’s (Pharmalucence, Bedford, MA)
instructions to generate Tc99m-labeled sulfur colloid particles, as previously described[60].
The final labeled sulfur colloid preparation is isotonic and at neutral pH.
The adjuvant activity mediated by IL-1α/IL-1β is not due to contaminating bacterial
components (i.e., endotoxin) since IL-1-containing vaccine formulations did not exhibit
adjuvant activity in IL-1 receptor deficient mice while control vaccine formulations utilizing
cholera toxin as the adjuvant exhibited adjuvant activity in IL-1 receptor deficient mice
comparable to that observed in wild-type mice (data not shown). Vaccine formulations were
prepared in endotoxin-free Dulbecco’s phosphate buffered saline with calcium and
magnesium (Mediatech Inc., Manassas, VA).
Mouse immunization, DTH and challenge
Nasal and subcutaneous immunization of mice with tetanus toxoid or PspA was performed
as indicated in the legends for Tables 1 and 2. For intranasal immunization, mice were
briefly anesthetized with isoflurane. DTH ear swelling measurements were performed as
previously described [46,61]. Tetanus toxin challenge was performed by subcutaneous
injection of 10 LD50 tetanus toxin diluted in gelatin/PBS with subsequent monitoring of
mice for signs of morbidity [62]. Streptococcus pneumoniae (strain A66.1) challenge was
performed by intravenous injection of 1.125 × 105 CFU diluted in HBSS with subsequent
monitoring of mice for 14 days for signs of morbidity [63–65].
Rabbit immunization, temperature monitoring, sample collection and anesthesia
For experiments in rabbits using tetanus toxoid, NZW rabbits (3 rabbits per group) were
intranasally (i.n.) or intramuscularly (IM) immunized on days 0, 28 and 56 with TT (100 μg)
and the indicated dose of rhuIL-1β. The vaccine was prepared in a total volume of 200 μL
sterile PBS and delivered in the hind leg (200 μl in a single injection) for the IM groups
(brief physical restraint). For nasal immunization, awake rabbits (brief physical restraint),
received 100 μl of the vaccine formulation per nostril delivered using a laboratory pipette.
Blood was collected into vacutainers from the central ear artery of sedated rabbits using
butterfly needles on days 21, 49 and 77 and then centrifuged at 3000 xg for 20 minutes to
obtain serum. Body temperature was monitored using a temperature transmitter surgically-
implanted in the rabbit abdomen prior to the study (Mini Mitter Co., Bend, OR).
For experiments in rabbits using recombinant protective antigen (rPA), NZW rabbits (4 – 8
rabbits per group) were intramuscularly immunized by injecting 10 μg rPA + alum (350 μg)
in 100 μl PBS on days 0, 21 and 42 using alternate thighs for vaccination. A dose of 10 μg
rPA was selected for the intramuscular immunization since this dose of rPA is known to
provide complete protection in rabbits against an anthrax spore challenge when delivered
intramuscularly with alum on days 0 and 28[66]. For nasal immunization, a 2-fold higher
dose of rPA was selected since we expected a higher dose of rPA would be needed to allow
nasal immunization to be as effective as intramuscular immunization due to differences
between parenteral injection and topical nasal delivery of antigen[67]. Rabbits were
intranasally immunized on days 0, 21 and 42 [68] with rPA (20 μg) and the indicated dose of
rhuIL-1α in a total volume of 200 μL sterile PBS (100 μL per nostril) using a laboratory
pipette. Blood was collected and prepared as previously described on days 21, 42 and 56.
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Depending on the experiment, rabbits were held on their backs and nasally immunized while
awake and under brief physical restraint or under sedation/anesthesia with: a) intramuscular
acepromazine (1 mg/kg) + butorphanol (1 mg/kg), b) intramuscular acepromazine (1 mg/kg)
+ inhalation isoflurane (4% at 4 mLs per min until there was no response to toe pinch reflex
test), or c) intramuscular ketamine (17.5 mg/kg) + xylazine (2.5 mg/kg). Acepromazine +
butorphanol sedated the rabbit but the rabbit remained conscious, upright and mobile in its
cage. Acepromazine + isoflurane provided sedation due to the use of acepromazine with
isoflurane providing deep anesthesia that was of short duration with the rabbit conscious,
upright and mobile in its cage within 5 minutes after receiving the nasal vaccine. Ketamine
+ xylazine provided deep anesthesia with the rabbits remaining deeply anesthetized for at
least 30 minutes after receiving the nasal vaccine. All rabbits were held on their backs for an
additional 30 sec after nasal immunization before being returned to an upright position and
placed in their cage, except for the ketamine + xylazine-anesthetized rabbits which were
placed on their sides and kept warm until they regained consciousness.
ELISA
A standard ELISA using alkaline phosphatase-conjugated anti-mouse detection antibodies
(Southern Biotech, Birmingham, AL) and PNPP substrate was used to measure tetanus
toxoid and PspA-specific IgG ands IgA antibodies in serum and vaginal lavage (used to
evaluate antigen-specific mucosal immunity at sites anatomically distant from the site of
immunization) as previously described except that plates were coated with tetanus toxoid or
PspA, respectively, at 2 μg/ml[46,69]. This same technique was used to measure tetanus
toxoid-specific antibody responses in rabbits after nasal or intramuscular immunization with
tetanus toxoid except that alkaline phosphatase-conjugated anti-rabbit IgG and IgA detection
reagents were used (Bethyl Laboratories, Montgomery, TX).
Anthrax protective antigen-specific serum responses were determined using ELISA
performed as previously described [70,71] using 2 μg/mL of rPA diluted in carbonate/
bicarbonate buffer as coating antigen, alkaline phosphatase-anti-rabbit IgG (Bethyl
Laboratories, Montgomery, TX) detection antibody and AttoPhos substrate (Promega;
Madison, WI).
Serum samples were diluted 1:32 or 1:64 (log2 1:25 or 1:26 ) followed by additional 2-fold
dilutions to allow determination of the end-point titer. Regardless of the ELISA method
used, the endpoint titer represents the last immune sample dilution that provided an ELISA
raw data value at least 3-fold higher than the value of the corresponding naïve sample at the
same dilution. The ELISA titers presented in the manuscript represent geometric mean titers
with log2 titers used for statistical analysis. Serum samples with undetectable ELISA titers
were assigned a log2 value one dilution lower than the starting dilution for calculation of
geometric mean titers and performance of statistical comparisons.
In vitro LeTx neutralization assay
A macrophage toxicity assay using J774A.1 mouse macrophage cells (ATCC #TIB-67;
Manassas, VA) was used to assess the ability of anti-PA antibody present in rabbit serum
samples to neutralize lethal toxin. The standard assay was performed as previously described
[71] in which serum (starting dilution of 1:16 or 1:24) was pre-incubated with LeTx except
that the final concentration of rPA and rLF in the serum-LeTx mixture applied to the J774A.
1 cells was 93.8 ng/mL of rPA and 93.8 ng/mL of rLF. Percent neutralization was calculated
using the following formulation: (Sample OD value–LeTx Standard OD value) ÷ (Cells only
OD value–LeTx Standard OD value) × 100. The optical density of a media only well (i.e. no
cells) was subtracted from all values before calculating percent neutralization. The
percentage cell viability at each serum dilution was plotted versus serum log2 dilutions using
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a second order polynomial curve and the serum dilution able to neutralize 50% of LeTx
(NT50) was calculated. Samples that had no detectable lethal toxin neutralizing activity were
assigned a value of 3 (one log2 dilution below the starting serum dilution) for statistical
analysis.
2-Dimensional Gamma scintigraphy
Rabbits were sedated/anesthetized using methods described above. The radio-labeled sulfur
colloid particles (Tc99m-SC ) were delivered in 100 μl PBS to the left nostril of the rabbits.
Animals were positioned upright, and then imaged 2-dimensionally, laterally from the left
side using an Anger camera with a medium energy, parallel hole collimation. Imaging
commenced immediately (time 0) after nasal delivery of the Tc99m-SC and animals were
subsequently re-imaged at time points: 30, 60, 90, 120 and 180 minutes post-delivery.
Collected images were background subtracted and corrected for isotopic decay of the Tc99m-
SC. For assessment of nasal deposition and kinetics of clearance, regions of interest were
generated by computer program processing (Nuclear Mac, Scientific Imaging, Inc.) to
overlie the nasal cavity, and relied upon to estimate the initial deposition of Tc99m-SC and
its subsequent removal over time from the nasal epithelium. At neutral pH, Tc99m-SC is non
permeable to respiratory epithelial surfaces and thus removed by mucociliary clearance
mechanisms. The Tc99m binds to sulfur colloid with high efficiency (> 99.9%) when
performed aseptically using the manufacturer’s guidelines (CIS-US, Inc, Bedford, MA) and
remains stable for a 6 h period, post-preparation.
Statistical analysis
ANOVA with Tukey’s multiple comparison test was used to compare vaccine-induced
antibody responses (ELISA titers, lethal toxin neutralizing antibody titers, DTH) between
multiple groups (Tables 1, 2 and 3 and Figure 4). Survival after challenge was compared
between vaccinated and control groups using the Fisher’s Exact Test (Tables 1 and 2).
Survival curves (for Streptococcus pneumoniae challenge) were compared using a Gehan-
Breslow-Wilcoxon Test. ANOVA followed by Dunnett’s test to compare the post-
vaccination temperatures to the time 0 temperature was used to evaluate change in body
temperature after vaccination of rabbits with IL-1 adjuvanted vaccines. Due to the non-
parametric distribution of the data points, the Mann Whitney test was used to compare
serum anti-TT IgG titers between the rabbit nasal and IM groups (Figure 3) and total and
nasal deposition of sulfur colloid (Figures 5B, 5C). An unpaired Student’s T-test was used to
compare nasal clearance of the colloidal particles at each time point in rabbits (Figure 5E)
and the area under the curve (Figure 5F). All analysis was performed using PRISM software
(GraphPad Software, La Jolla, CA). p≤0.05 was considered significant.
RESULTS
IL-1β is an effective nasal vaccine adjuvant in mice for the induction of protective
immunity against a systemic Streptococcus pneumoniae challenge
An important aspect of mucosal immunization is that it elicits mucosal immunity in addition
to systemic protective immunity. However, because of recent interest in needle-free methods
of immunization [1,4,9] we have looked to mucosal immunization because it can be used to
elicit systemic protection against pathogens and toxins, without the necessity of an injection.
Studies were performed to evaluate the nasal adjuvant activity of IL-1β in mice using
pneumococcal surface protein A (PspA) as the antigen to determine if nasal immunization
was as effective as parenteral immunization using the FDA-approved adjuvant alum for the
induction of antigen-specific serum IgG and protection against a lethal bacterial challenge.
Female BALB/c mice (17–19 per group) were nasally immunized with 1 μg PspA alone or
combined with 5 μg IL-1β on days 0, 21 and 42 (Table 1). A systemic immunization control
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consisted of mice immunized subcutaneously with 1 μg PspA + alum on days 0, 21 and 42.
Serum samples collected on day 71 demonstrated that needle-free nasal immunization with
PspA + IL-1β induced serum anti-PspA IgG titers (1:50,766) that were significantly greater
than serum anti-PspA IgG titers in mice immunized with antigen alone (<1:32, p<0.05).
Although the serum anti-PspA IgG titers induced by nasal immunization with PspA + IL-1β
were 2.7 fold lower than those induced in mice immunized subcutaneously (1:135,942), the
difference was not significant. Only mice nasally immunized with PspA + IL-1β developed
significantly increased mucosal IgA responses (1:37; p<0.05 vs intranasal PspA alone or
subcutaneous PspA + alum). On day 72, all mice were challenged by the intravenous route
with 1.125 × 105 CFU Streptococcus pneumoniae strain A66.1 and monitored for signs of
morbidity for 14 days. Of the mice nasally immunized with PspA + IL- 1β, 68% were
protected against morbidity (p<0.0001 vs mice immunized with PspA alone). Protection
against death induced by nasal immunization with PspA + IL-1β was identical to that
observed in mice immunized subcutaneously with PspA + alum (68%). Both the nasal
vaccine using IL-1β as an adjuvant and the subcutaneously-administered positive control
vaccine provided a significantly increased median time to morbidity (greater than 14 days)
as compared to mice immunized nasally with PspA alone (median time to morbidity of 3
days; p<0.0001 vs mice immunized with PspA + adjuvant). Thus, needle-free nasal
immunization of mice utilizing IL-1β as a vaccine adjuvant is as effective as subcutaneous
immunization for the induction of antigen-specific serum IgG antibody titers and protection
against a lethal intravenous challenge with Streptococcus pneumoniae while also inducing
mucosal IgA responses.
IL-1β is an effective nasal vaccine adjuvant in mice for the induction of protective
immunity against a systemic tetanus toxin challenge
To confirm the efficacy of nasal immunization using IL-1β as the adjuvant with a different
protein antigen, female BALB/c mice (9–17 per group) were immunized with 50 μg tetanus
toxoid (TT) by the subcutaneous or nasal routes on days 0, 21 and 42. ISA-51[54], a water-
in-oil emulsion adjuvant that has been used in human clinical studies[72,73], was used as the
adjuvant for the subcutaneous immunization control while mice nasally immunized with TT
alone served as the antigen alone control. The remaining mice were divided into two large
subgroups; one subgroup was nasally immunized on days 0, 21 and 42 with TT combined
with adjuvant (CTx or IL-1β at 0.2, 1 or 5 μg) while another subgroup was immunized on
day 0 with TT combined with adjuvant while mice were boosted on days 21 and 42 with
antigen alone (see the legend for Table 2 for more details). This experiment was designed to
determine if the use of adjuvant with only the priming immunization was sufficient for the
induction of protective immunity.
As shown in Table 2, nasal immunization of mice with 50 μg TT alone was minimally
immunogenic and induced a day 56 anti-TT IgG titer of 1:1,176. In contrast, nasal
immunization with TT + IL-1β (0.2, 1 or 5 μg) on days 0, 21 and 42 induced, in a dose
dependent fashion, significantly higher levels of serum anti-TT IgG on day 56 when
compared to mice nasally immunized with antigen alone (p<0.05). Day 56 serum geometric
mean antibody titers for the 0.2, 1 and 5 μg IL-1β groups were 1:138,250, 1:297,353 and
1:356,722, respectively. CTx used as a control mucosal adjuvant induced a day 56 serum
anti-TT IgG titer of 1:671,553. IL-1β at 1 and 5 μg doses induced serum IgG titers that were
not significantly different than those induced by CTx. Of the nasally immunized groups that
used adjuvant with each immunization, only the TT + 0.2 μg IL-1β group had a serum anti-
TT IgG titer significantly lower than that induced by subcutaneous immunization with TT +
ISA-51 (Table 2, p<0.05).
The use of adjuvants only with the day 0 immunization also induced serum anti-TT IgG
titers that were significantly increased above titers in mice immunized with antigen alone
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(Table 2, p<0.05). Day 56 serum geometric mean antibody titers for the day 0 IL-1β groups
0.2, 1 and 5 μg were 1:65,536, 1:98,527 and 1:94,848, respectively. CTx used as an adjuvant
at day 0 only induced a day 56 serum anti-TT IgG titer of 1:446,787. Despite significant
adjuvant activity for all IL-1β groups, all IL-1β groups had serum anti-TT IgG titers
significantly lower than those induced when CTx was used as an adjuvant with only the day
0 vaccination (p<0.05). All groups that utilized IL-1β as an adjuvant at day 0 only had serum
anti-TT IgG titers significantly lower than that induced by subcutaneous immunization with
TT + ISA-51 (Table 2, p<0.05).
Although mucosal immunity is not required for protection against tetanus toxin, vaginal
anti-TT IgA titers were measured as an indicator of induction of mucosal immune responses
in the female reproductive tract since mucosal IgA at this site demonstrates the ability of
nasal immunization to induce IgA responses at distant mucosal tissues and IgA at this site
may be important in protection against sexually-transmitted diseases(Table 2). Only mice
immunized by the nasal route with antigen combined with adjuvant (CTx or IL-1β) had
vaginal IgA responses that were significantly increased compared to mice nasally
immunized with TT alone (i.e., no adjuvant; p<0.05) or mice subcutaneously immunized
with TT + ISA-51 (p<0.05). Mice immunized with 50 μg TT + 5 μg IL-1β on days 0, 21 and
42 had the absolute highest vaginal anti-TT IgA response with a titer of 1:1,448. However,
there were no significant differences for the vaginal anti-TT IgA between any of the nasal
immunization groups that utilized adjuvant (CTx or IL-1β).
Delayed type hypersensitivity (DTH) responses were measured using an ear swelling assay
at day 56 as a method to measure vaccine-induced T cell-mediated immunity in vivo (Table
2). Mice immunized with TT + ISA-51 subcutaneously and mice immunized nasally with
TT + adjuvants for all three immunizations (day 0, 21 and 42) or TT + CTx or IL-1β (5 μg)
administered with the day 0 immunization only had TT-specific DTH responses that were
significantly greater than TT-specific DTH responses measured in mice immunized nasally
with TT alone (p<0.05). TT-specific DTH responses induced by IL-1β were significantly
less than DTH responses induced by nasal immunization with TT + CTx using the same
adjuvant schedule (p<0.05) or subcutaneous immunization using TT + ISA-51 (p<0.05).
Mice were challenged at day 60 by the intraperitoneal route with 10 LD50 of tetanus toxin
and monitored for signs of morbidity to determine the protective capacity of the various
vaccine groups. Mice nasally immunized with TT alone exhibited 10% survival while all
adjuvant groups demonstrated 100% protection against morbidity (p=0.048, Fisher’s Exact
test). Our results demonstrate that IL-1β was an effective adjuvant for needle-free nasal
immunization that induced complete protection against a parenteral toxin challenge. Despite
significant differences in the serum anti-TT IgG titers between some of the nasal groups as
compared to the IM control group (Table 2), adjuvanted nasal immunization was as effective
as parenteral immunization for the induction of protective immunity. Additionally, use of
adjuvant with the priming immunization only (in a three dose vaccination regimen) was
sufficient for the induction of significantly elevated serum IgG, mucosal IgA, DTH and
protective immunity.
Evaluation of the safety and efficacy of IL-1β used as a nasal vaccine adjuvant in rabbits
when coadministered with tetanus toxoid
Studies are needed to assess the efficacy of IL-1 as a nasal vaccine adjuvant in larger
animals, such as rabbits, that contain a nasal cavity anatomy more closely related to
humans[74,75]. Rabbits are also used to evaluate the pyrogenic nature of pharmaceuticals
for use in humans[76–78]. Since IL-1 has both vaccine adjuvant and pyrogenic
activities[79–81] when delivered parenterally, this experiment was performed to evaluate
both the adjuvant and pyrogenic activity of IL-1 when used as an adjuvant for nasally-
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administered vaccines and to compare the efficacy of nasal immunization to parenteral
immunization. In this experiment, awake rabbits were nasally or intramuscularly immunized
with 100 μg of tetanus toxoid (TT) combined with increasing doses of rhuIL-1β (0.5, 12.5,
312.5 or 7812.5 ng/kg; approximately 1.25 ng, 31.25 ng, 0.781 μg or 19.5 μg per 2.5 kg
rabbit, respectively) on days 0, 28 and 56. Since IL-1 could serve as a positive control
adjuvant and pyrogen [79–81], rhIL- 1β was used as the adjuvant for the intramuscularly
immunized rabbits. Changes in core body temperature were monitored immediately before
and at 2, 4, 6, 8, 24 and 48 hours after each vaccination. As shown in Figure 1, rabbit core
body temperature significantly increased at 2 and 4 hours after intramuscular immunization
with TT + 312.5 ng/kg of IL-1β (p<0.05) and at 2, 4, 6 and 8 hours after IM immunization
with 7812.5 ng/kg of IL-1β (p<0.05). In contrast, there were no significant changes in core
body temperature at any time point after nasal immunization with TT + IL-1β (0.5, 12.5,
312.5 or 7812.5 ng/kg). Thus, although intramuscular administration of IL-1β at 312.5 and
7,812.5 ng/kg induced fever, nasally-delivered IL-1β in rabbits did not.
Serum anti-TT IgG was measured by ELISA on days 21, 49 and 77 to compare the efficacy
of intranasal immunization to intramuscular immunization. Day 21 serum anti-TT IgG titers
in rabbits nasally immunized with TT + IL-1β were highly variable and did not demonstrate
a dose response to IL-1β. Serum anti-TT IgG responses at day 21 in rabbits nasally
immunized with TT + IL-1β ranged from undetectable (one rabbit in the 12.5 ng/kg and one
rabbit in the 7,812.5 ng/kg) to a peak titer of 1:65,536 in a rabbit nasally immunized with TT
+ 0.5 ng/kg IL-1β (Figure 2). Serum anti-TT IgG titers at day 21 in rabbits intramuscularly
immunized with TT + IL-1β also did not demonstrate a dose response to IL- 1β although
serum anti-TT titers were consistently elevated, ranging from 1:524,288–1:2,097,152
(Figure 2). By day 49, three weeks after the day 28 boost, serum anti-TT IgG titers remained
highly variable in animals immunized by the nasal route while serum anti-TT IgG titers in
rabbits intramuscularly immunized remained consistently elevated with titers ranging from
1:262,144 to 1:33,554,432 (Figure 2). In some nasally immunized rabbits, serum anti-TT
IgG titers were comparable to anti-TT IgG titers induced by intramuscular immunization.
For example, one rabbit nasally immunized with TT + 0.5 ng/kg IL-1β had a day 49 serum
anti-TT IgG titer of 1:1,048,576 while titers of 1:262,144 and 1:524,288 were detected in
rabbits nasally immunized using TT + IL-1β at 12.5 or 312.5 ng/kg, respectively (Day 49,
Figure 2). Even after three immunizations, serum anti-TT IgG titers at day 77 in rabbits
nasally immunized with TT + IL-1β remained highly variable with titers ranging from
undetectable to 1:1,048,576 while serum anti-TT IgG titers in rabbits intramuscularly
immunized were consistently elevated with titers as high as 1:16,777,216 (Day 77, Figure
2). Our results suggest that intranasal immunization with TT + IL-1β has the potential to
induce high-titered serum anti-TT IgG responses comparable to that induced by
intramuscular immunization although the serum anti-TT IgG responses induced by
intranasal immunization are unacceptable due to the extensive animal-to-animal variation.
To evaluate the overall performance of nasal immunization as compared to intramuscular
immunization, we combined the day 77 serum anti-TT IgG titers from all rabbits immunized
nasally with TT + IL-1β (all doses) and compared them to the serum anti-TT IgG titers of all
rabbits immunized intramuscularly with TT + IL-1β (all doses). The serum anti-TT IgG
geometric mean titer (GMT) in nasally immunized rabbits was 1:21,081 (range 1:32 to 1:
1,048,576.) while the serum anti-TT IgG GMT in intramuscularly immunized rabbits was
1:4,194,304 (range 1:524,288 to 1:16,777,216) (Figure 3), a 198-fold difference in GMT
between IN and IM immunization (p=0.0001). If we compare the maximum day 77 serum
IgG titer in a nasally immunized rabbit (1:1,048,576; TT + 312.5 ng/kg IL-1β) with the
maximum day 77 serum IgG titer in an intramuscularly immunized rabbit (1:16,777,216; TT
+ 312.5 ng/kg IL-1β), the maximum serum anti-TT IgG titer after nasal immunization is 16-
fold less than the maximum serum anti-TT IgG titer induced after intramuscular
Gwinn et al. Page 9













immunization. Regardless of the comparison to the anti-TT IgG titers induced by
intramuscular immunization, the serum anti-IgG titers induced by nasal immunization were
extremely variable. This lack of reproducible induction of serum IgG responses after nasal
immunization in rabbits using IL-1β as the adjuvant is in contrast to the efficacy of nasal
immunization observed in mouse models where the antigen-specific serum IgG titers
induced by nasal immunization using IL-1β as an adjuvant were highly reproducible and
within 3-fold of the antigen-specific serum IgG titers induced by subcutaneous
immunization (Tables 1 and 2).
Nasal immunization with TT + IL-1β failed to induce detectable fecal anti-TT IgA responses
although fecal anti-TT IgG responses were detectable in some groups (data not shown).
Thus, nasally delivered IL-1β lacked the adverse effects (pyrogenicity) observed when IL-1β
was delivered intramuscularly although nasal immunization of rabbits was not as effective
as intramuscular immunization for the consistent induction of high-titered, antigen-specific
serum IgG.
Evaluation of the efficacy of IL-1α used as a nasal vaccine adjuvant in rabbits when
coadministered with anthrax protective antigen. The state of anesthesia influences the
efficacy of nasal immunization in rabbits
The rabbit nasal immunization experiments described above in Figures 1 – 3 using TT +
IL-1β were performed in rabbits that were awake. The use of anesthesia is known to enhance
the immunogenicity of nasally delivered vaccines in mice [48, 49], including studies that
have utilized anthrax protective antigen as the immunogen. However, the impact the use of
anesthetics has on the efficacy of nasal immunization in rabbits is not known.
To determine if the use of anesthesia influenced the immunogenicity of nasal immunization
in rabbits, rabbits were nasally immunized while awake or anesthetized with agents
providing various depths of anesthesia. Acepromazine combined with butorphanol was
utilized to sedate the rabbits. With this treatment, rabbits were sedated but remained
conscious, upright and mobile within the cage. Acepromazine sedation followed by
isoflurane anesthesia was used to provide a temporary deep anesthesia that was of short
duration with the rabbit conscious, upright and mobile in its cage within 5 minutes after
receiving the nasal vaccine. Ketamine + xylazine provided deep anesthesia with the rabbits
remaining deeply anesthetized for at least 30 minutes after receiving the nasal vaccine.
Anthrax recombinant protective antigen (rPA) was used as the vaccine immunogen to allow
a comparison between the results from this current study and previously published work that
utilized rPA as an immunogen for nasal delivery to awake or ketamine-anesthetized
rabbits[68,82]. IL-1α was used as the adjuvant to evaluate the adjuvant activity of IL-1α
when nasally delivered to rabbits [37,55]. rPA (20 μg) was adjuvanted with rhuIL-1α (5 or
15 μg) and delivered nasally to female NZW rabbits (4–8 per group) on days 0, 21 and 42
while awake, sedated with acepromazine + butorphanol, sedated with acepromazine and
anesthetized with isoflurane or deeply anesthetized with ketamine + xylazine. Intramuscular
immunization with rPA (10 μg) + alum on days 0, 21 and 42 was used to represent a
parenteral immunization regimen that may be used in humans to induce protective immunity
against anthrax and therefore anesthetics were not used in this group[66]. Serum collected
on days 42 and 56 was tested for the presence of anti-PA IgG titers by ELISA. As shown in
Figure 4, day 42 serum anti-PA IgG titers from rabbits nasally immunized while under deep
anesthesia with ketamine + xylazine were significantly higher (p<0.05) compared to rabbits
nasally immunized while awake, acepromazine + butorphanol-sedated or acepromazine +
isoflurane anesthetized and comparable to serum anti-PA IgG titers in rabbits immunized
intramuscularly with rPA (10 μg) + alum on days 0, 21 and 42. On day 56, serum anti-PA
IgG geometric mean titers in the ketamine + xylazine group (1:4.98 × 106) were
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significantly greater (p<0.05) than anti-PA IgG titers in rabbits that were awake (1:32,768)
or sedated with acepromazine + butorphanol (geometric mean 1:32,768) but comparable to
anti-PA IgG titers in rabbits nasally-immunized while treated with aceopromazine/isoflurane
(1:623,487) or immunized intramuscularly (geometric mean 1:1.995 × 107; Figure 4). Our
results demonstrate that deep anesthesia induced by ketamine + xylazine enhanced the
induction of more consistent and elevated serum IgG responses with less variation in serum
PA-specific IgG titers on days 42 and 56 as compared to other nasally vaccinated groups.
Fecal anti-PA IgA and IgG were also measured at day 56 with geometric mean anti-PA IgG
and IgA titers less than 1:6 in all of the groups of rabbits nasally immunized with rPA + IL-
1α (data not shown).
Serum lethal toxin neutralizing antibodies were also measured to determine if the use of
anesthetics influenced the induction of protective serum antibodies after nasal immunization.
Of the nasally immunized rabbits, serum LeTx neutralizing activity (NT50 titer) was highest
in animals that were anesthetized with ketamine + xylazine (LeTx NT50 of 1:539.6, Table 3)
and significantly higher compared to rabbits treated with acepromazine + butorphanol (LeTx
NT50 of 1:26.4, Table 3, p<0.05). Although the use of anesthetics with nasal immunization
enhanced the induction of serum LeTx neutralizing antibody responses, IM immunization
with rPA + alum induced serum LeTx NT50 titers (1:29,303) significantly greater than NT50
titers induced by any nasal immunization group (p<0.05).
Anesthesia influences nasal clearance rates in rabbits
We hypothesized that nasal vaccination was more effective in deeply anesthetized rabbits
due to enhanced vaccine delivery or altered nasal clearance. To test these hypotheses, we
utilized gamma scintigraphy to monitor nasal delivery and clearance[83,84] in sedated
(acepromazine + butorphanol) or anesthetized (ketamine + xylazine) rabbits. Rabbits were
administered Tc99m-sulfur colloid intranasally (in a volume of 100 μl to a single nostril)
while sedated with acepromazine + butorphanol or while deeply anesthetized with ketamine
+ xylazine. Rabbits were imaged immediately after nasal delivery to evaluate the efficacy of
nasal delivery to sedated or deeply anesthetized rabbits. A typical scintigraphy image
immediately after nasal delivery is presented in Figure 5A. Total activity delivered per
rabbit (3–4 per group) was calculated as a percentage of the calculated stoichiometric
delivery and the state of anesthesia did not influence total activity delivered (Figure 5B;
p=0.8571, Mann Whitney). We used computer programming to quantify regional activity
delivered only within the target site of the nasal cavity, immediately after delivery. One
rabbit in the ketamine + xylazine group aspirated the radiolabeled sulfur colloid to the lungs
and stomach at the time of delivery resulting in one rabbit with a greatly reduced amount of
sulfur colloid in the nasal cavity (22.5% of expected; Figure 5C). However, the state of
anesthesia did not significantly influence nasal cavity deposition (at time zero) of the sulfur
colloid (p=0.6286, Mann Whitney, Figure 5C). Figure 5D contains the scintigraphy image of
the rabbit that aspirated sulfur colloid at the time of nasal delivery with sulfur colloid
immediately appearing in the lungs and stomach (verified by removal of organs after
euthanasia). Rabbits were monitored over time (30, 60, 90, 120 and 180 minutes) to
determine if the state of anesthesia influenced clearance of the sulfur colloid through the
nasal cavity. As shown in Figure 5E, nasal clearance of Tc99m-sulfur colloid was decreased
in rabbits anesthetized with ketamine + xylazine as compared to rabbits sedated with
acepromazine + butorphanol. At 30 minutes after nasal delivery, 88.9 ± 15.7% of sulfur
colloid measured in the nasal cavity at time 0 (calculated from Figure 5C) remained in the
nasal cavity of ketamine + xylazine anesthetized rabbits while only 44.38 ± 20.9% of
delivered sulfur colloid remained in the nasal cavity of acepromazine + butorphanol sedated
rabbits (p=0.0597). Sulfur colloid could be detected in the bedding of acepromazine ±
butorphanol sedated rabbits at 30 minutes post nasal delivery indicating a large fraction of
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the labeled sulfur colloid that had been initially delivered to the nasal region, was lost from
the nasal cavity by non-physiologic means, within 30 minutes of delivery (data not shown).
Sulfur colloid could not be detected in the bedding of ketamine + xylazine anesthetized
rabbits. The amount of radiolabeled sulfur colloid remaining in the nasal cavity at 60
minutes after nasal delivery was significantly greater in ketamine + xylazine anesthetized
rabbits (76.17 ± 22.75% of expected) than in the acepromazine + butorphanol rabbits (33.75
± 12.76% of expected; p=0.0245)). There was no difference between the amount of
radiolabeled sulfur colloid in the nasal cavity of ketamine + xylazine and the acepromazine
+ butorphanol rabbits at 90, 120 or 180 minutes after nasal delivery. Using the data from
Figure 5E, the calculated 50% clearance time in acepromazine + butorphanol sedated rabbits
was 24 minutes while the 50% clearance time in ketamine + xylazine anesthetized rabbits
was 100 minutes. The total area under the curve (AUC) was calculated for the nasal
clearance curves in Figure 5E, and the ketamine + xylazine anesthetized rabbits produced a
total AUC of 10,881 ± 2,927 (percent minutes) while the AUC for the acepromazine +
butorphanol rabbits was 6,744 ± 1,704, (p=0.063; Figure 5F). Figure 5G shows a typical
scintigraphy image of Tc99m-sulfur colloid 180 minutes after nasal delivery with activity
divided between the nasal cavity and stomach. Mucociliary clearance moved a portion of the
sulfur colloid through the nasal cavity and it was then swallowed with no activity detected in
the lungs. Of a total of 7 rabbits tested using gamma scintigraphy, 6 of 7 rabbits had results
similar to Figure 5G; only one rabbit had activity detectable in the lung after nasal delivery.
Our results suggest that the depth of anesthesia influences the immunogenicity of nasally-
delivered vaccines secondary to retention within the nasal cavity with a deeply anesthetized
state providing increased nasal retention.
DISCUSSION
In this study we have demonstrated that recombinant interleukin 1α and β are effective
vaccine adjuvants when nasally delivered to mice or rabbits. IL-1 was an effective nasal
vaccine adjuvant in mice for the induction of antigen-specific serum IgG and mucosal IgA
and protection against systemic challenge with tetanus toxin or Streptococcus pneumoniae.
Although IL-1 was pyrogenic when delivered intramuscularly to rabbits, IL-1 did not exhibit
pyrogenic activity when used as a nasal vaccine adjuvant. The efficacy of nasal
immunization in rabbits was significantly influenced by the use of anesthesia at the time of
immunization with deeper anesthesia correlating with increased immunogenicity of the
nasally delivered vaccine. Deep anesthesia (ketamine + xylazine) resulted in improved nasal
retention of Tc99m-sulfur colloid and suggested that nasal immunization techniques that
improve nasal retention of the vaccine should increase the immunogenicity of the vaccine.
Our results in mice demonstrated that effective nasal immunization induced antigen-specific
serum IgG responses comparable to those induced by parenteral immunization.
Additionally, protection against systemic toxin or bacterial challenges induced by nasal
immunization was comparable to protection induced by parenteral immunization. The
protection observed against lethal challenge with Streptococcus pneumoniae A66.1 provided
by nasal immunization of mice with PspA + IL-1 was comparable to protection observed by
other groups that have utilized nasal immunization of mice with PspA (100 ng) + native or
mutant CT (5 μg)[63]. Our murine studies support the conclusions that 1) IL-1 is an
effective nasal vaccine adjuvant and 2) nasal immunization provides a needle-free method of
immunization able to induce protective systemic immunity comparable to protection
provided by a vaccine delivered with a needle.
Nasal immunization of mice with antigen combined with IL-1 supported the induction of
antigen-specific IgA in mucosal secretions. The use of IL-1 as an adjuvant was required for
the induction of IgA responses since immunization with antigen alone failed to induce
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detectable antigen-specific IgA. Although mucosal IgA responses were not required for
protection in our murine challenge studies, the use of a mucosal route of immunization able
to induce mucosal IgA responses may be beneficial for protection against pathogens that
infect via the mucosal surfaces of the host [85]. Despite the expected mucosal IgA results in
nasally-immunized mice, nasal immunization of rabbits did not induce detectable antigen-
specific IgA responses. Our results agree with results from others that have reported nasal
immunization of rabbits with rPA combined with adjuvant induced minimal or undetectable
antigen-specific IgA responses in nasal secretions [86]. Nasal immunization of rabbits with
influenza antigen also failed to induce detectable antigen-specific mucosal IgA [87].
Although rabbits provide a convenient non-rodent species for the performance of vaccine
studies, the lack of induction of mucosal IgA responses after nasal immunization of rabbits
is puzzling. It is not clear if the lack of detectable mucosal IgA responses in rabbits after
nasal immunization is due to vaccine formulation issues such as antigen dose (since
induction of mucosal IgA may be antigen dose-dependent [88]) or if rabbits, in contrast to
mice, do not develop significant mucosal IgA responses after nasal immunization.
Additional studies in rabbits are needed to identify the vaccine/vaccination parameters that
influence the induction of antigen-specific mucosal IgA responses after nasal immunization.
Safety must always be evaluated when a new vaccine formulation is developed. IL-1 is
known to exhibit pyrogenic activity[81] and human clinical studies that evaluated IL-1 for
cancer treatment reported a variety of adverse events for parenterally delivered IL-1
including fever, chills and hypotension[89]. We selected rabbits as an animal model in our
studies since rabbits have a nasal cavity anatomy that is more similar to the human nasal
cavity (as compared to mice[74]) and rabbits are often used to test the pyrogenicity of
substances before their use in humans[76–78]. IL-1 has been used in human clinical studies
at up to 1.0 μg/kg [89]. We tested IL-1β in rabbits at doses of 0.5, 12.5, 312.5 and 7,812.5
ng/kg (0.0005 μg/kg - 7.8 μg/kg) to provide an extensive range of IL-1 doses to allow us to
effectively evaluate the pyrogenicity of IL-1β when delivered nasally and to use an IL-1
dose greater than that used in human studies when delivered parenterally to determine if a
higher IL-1β dose could be used nasally as a vaccine adjuvant without exhibiting pyrogenic
effects. The doses of IL-1β we evaluated in rabbits were comparable to those used by others
to evaluate the pyrogenic activity of IL-1β in rabbits[90]. Others have reported that 100 μg
of recombinant ovine IL-1β provided both adjuvant and pyrogenic activity when delivered
parenterally to sheep[79]. Confirming the pyrogenic activity reported for IL-1 in human,
rabbit and sheep studies, we observed significant pyrogenic activity when IL-1β was
delivered intramuscularly to rabbits at 312.5 or 7,812.5 ng/kg. However, IL-1 delivered
nasally induced no significant change in core body temperature suggesting that topical
mucosal delivery of IL-1 as a mucosal vaccine adjuvant attenuates systemic adverse effects
observed when the same dose of IL-1 is delivered parenterally. Despite the variability of
anti-TT serum IgG responses induced in rabbits by nasal immunization with TT + IL-1β,
rabbits nasally immunized with TT + 0.5 ng/kg IL-1β had day 77 serum anti-TT IgG titers
of 1:32,768, 1:131,072 and 1:524,288 and 2 rabbits nasally immunized with TT + 312.5 ng/
kg IL-1β had day 77 anti-TT IgG titers of 1:524,288 and 1:1,048,576 with no measurable
fever suggesting that vaccine formulations containing IL-1β may safely induce vaccine-
specific antibody responses after nasal delivery while not inducing systemic adverse effects
such as fever. Since IL-1 is able to cause fever when injected directly into the brain of
rabbits at doses as low as 2.0 ng/kg IL-1β[91], our results suggest that despite the close
proximity of the nasal cavity to neuronal tissues of the central nervous system, nasally
delivered IL-1 did not directly access the central nervous system. In a separate study, we
also observed that nasal delivery of human GM-CSF and IL-1 as a vaccine adjuvant in non-
human primates did not induce the production of primate anti-human GM-CSF neutralizing
antibodies while intramuscular immunization with human GM-CSF formulated in a stable
oil in water emulsion in the presence of a TLR4 ligand as a vaccine adjuvant induced
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significant anti-human GM-CSF neutralizing antibodies[47]. The use of the stable emulsion
and TLR4 ligand likely contributed to the induction of anti-GM-CSF antibodies by
providing a depot effect in the context of TLR4-dependent signaling. In contrast, nasal
immunization with antigen combined with IL-1 and GM-CSF in saline was likely cleared
from the nasal cavity within a few hours (expected results similar to Figure 5E) reducing the
likelihood of induction of anti-cytokine antibodies that would reduce their adjuvant activity.
This observation suggests that nasal immunization with IL-1 may not induce neutralizing
anti-human IL-1 antibody responses. Collectively, our results suggest that topical nasal
delivery has the potential to minimize or eliminate adverse effects (fever, anti-adjuvant
immune responses) that may be observed when the adjuvants are delivered parenterally.
Our results are the first direct demonstration that the state of anesthesia influences the
immunogenicity of nasally-delivered vaccines in rabbits. Despite the variability in serum
antibody responses observed after nasal immunization of awake rabbits (Figure 2), nasal
immunization of rabbits anesthetized with ketamine + xylazine with rPA + IL-1α induced
serum anti-PA IgG titers that were significantly greater than the responses induced in rabbits
that were nasally immunized while awake or sedated. More importantly, nasal immunization
of rabbits anesthetized with ketamine + xylazine induced reproducible serum anti-PA IgG
and elevated lethal toxin neutralizing titers. Our rabbit results agree with results reported for
mice since the use of deep anesthesia enhanced the immunogenicity of nasally delivered
vaccines in mice[48,49]. A major issue that we currently face is how to translate our
observations using nasal immunization of anesthetized rabbits into the development and
optimization of effective nasal vaccines and nasal immunization strategies for use in
humans. Since our goal is to develop a needle-free method of immunization, the use of
injectable anesthetic agents is not practical for use in humans for the purpose of nasal
immunization. However, as discussed below, the use of optimized nasal immunization
methods should provide a nasal immunization method that effectively and reproducibly
induces the desired immune responses.
The induction of serum anti-PA IgG and LeTx neutralizing titers and the influence of the
anesthetic state after nasal immunization of rabbits observed in our study agree with results
reported by others that have evaluated nasal immunization of rabbits with rPA[68,82]. In our
study, nasal immunization of ketamine + xylazine anesthetized rabbits with 20 μg rPA +
IL-1α induced a day 56 serum anti-PA IgG geometric mean titer of 1:4.98 × 106 and serum
LeTx neutralization titer 50 (NT50) of 1:539. Others that performed nasal immunization of
rabbits anesthetized with ketamine/xylazine (personal communication, Vincent
Sullivan[68]) with a liquid formulation containing 50 μg of rPA + 50 μg CpG on days 0, 21
and 42 induced a day 56 serum anti-PA IgG titer of ~1:200,000 and consistently elevated
serum lethal toxin neutralizing antibody responses [68]. However, our study also determined
that nasal immunization of awake rabbits with 20 μg rPA + IL-1α induced low day 56 serum
anti-PA IgG and lethal toxin neutralizing antibody. This observation is confirmed in a study
by Wimer-Mackin[82] that reported very low (i.e., not significantly different from negative
control rabbits) serum anti-PA IgG ELISA responses and serum lethal toxin neutralizing
titers after nasal immunization of awake rabbits with a liquid vaccine formulation containing
90 μg of rPA + 25 μg of MPL as adjuvant on days 0 and 28. However, when they
formulated the vaccine as a dry powder containing the bioadhesive chitosan its
immunogenicity for the induction of serum anti-PA ELISA and toxin neutralizing antibody
responses was significantly increased[82]. It is tempting to speculate that the use of the dry
powder vaccine formulation containing the bioadhesive chitosan increased the nasal
retention of the vaccine (see below) to provide increased immunogenicity of nasally-
delivered vaccines in animals that were not anesthetized. Additional studies are needed to
optimize vaccine formulations so that nasal immunization in the absence of anesthesia
consistently induces protective serum antibody responses.
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Gamma scintigraphy determined that the superior immunogenicity of the nasal vaccine in
ketamine + xylazine anesthetized rabbits correlated with enhanced vaccine retention within
the nasal cavity of rabbits. The 50% clearance time in sedated rabbits was 24 minutes while
the 50% clearance time in ketamine + xylazine anesthetized rabbits was 100 minutes. Others
have utilized gamma scintigraphy in rabbits to evaluate the clearance of nasal vaccine
formulations [92] and determined that unmodified PLGA microspheres had a 50% clearance
time of 30 minutes while a chitosan modified PLGA microsphere formulation had a 50%
clearance time of 180 minutes. Immunogenicity studies in mice using the two PLGA
microsphere formulations determined that the chitosan modified PLGA microsphere with a
prolonged nasal clearance time was more immunogenic than the unmodified PLGA
microsphere and induced serum antibody responses comparable to those induced by
parenteral immunization[92]. Gamma scintigraphy studies in sheep determined that the 50%
clearance time for a control formulation was about 15 minutes while two chitosan
formulations had 50% clearance times of 43 and 115 minutes[93]. As mentioned above, a
dry powder vaccine formulation containing chitosan was significantly more immunogenic
when delivered to awake rabbits than a liquid vaccine lacking chitosan [82]. Although nasal
clearance studies were not performed in the study by Wimer-Mackin[82], the improved
immunogenicity of the vaccine formulation containing chitosan is consistent with increased
immunogenicity of vaccines due to increases in nasal clearance time. These observations
support our conclusion that increasing the nasal residence time of nasally-administered
vaccines may be required for optimal vaccine immunogenicity and that the use of
bioadhesives such as chitosan may represent a strategy to develop nasal vaccine
formulations that provide increased nasal residence time without the use of anesthetics.
The direct comparison of vaccine-induced immune responses between subjects nasally
immunized and those vaccinated with a needle (intramuscular, subcutaneous) suggests that
while nasal immunization may induce protective immunity comparable to that induced by
needle immunization, the quality and quantity of immune responses induced will vary
between those vaccinated intranasally or with a needle. In this study, nasal immunization of
mice with protein antigen + adjuvant (CT or IL-1) induced protective immunity and serum
IgG titers not significantly different than those induced by subcutaneous immunization.
However, serum IgG titers induced by nasal immunization were always lower than those
induced by parenteral immunization. The advantage of adjuvanted nasal immunization in the
mouse was the induction of mucosal IgA responses that were not induced by needle
immunization. In rabbits, even when using ketamine/xylazine anesthesia and a 2-fold greater
antigen dose, nasal immunization was not as effective as intramuscular immunization for the
induction of vaccine-induced toxin-neutralizing antibody responses, despite the induction of
serum anti-PA IgG ELISA titers that were statistically similar between the two routes of
immunization. Our results in mice are in agreement with comparisons made between the
injected inactivated influenza vaccine and the intranasal live attenuated influenza vaccine
where the nasal vaccine induced serum antibody responses lower than those induced by the
injected vaccine, despite similar efficacies[94,95]. The use of different vaccine formulations
(i.e., live attenuated influenza vs inactivated influenza virus) complicated the interpretation
of these results. However, when immune responses induced by nasal immunization of
humans with the inactivated influenza virus vaccine were compared to those induced by the
same vaccine delivered intramuscularly, nasal immunization was less effective than
intramuscular immunization for the induction of serum hemagglutination inhibiting (HAI)
antibodies[67]. Nasal immunization with a 4-fold greater dose of inactivated influenza
vaccine than that used for IM immunization was required to allow nasal immunization to
approach the efficacy of IM immunization based on the induction of serum HAI and
influenza virus neutralizing antibodies[67]. It is possible that if our rabbit rPA nasal
immunization studies had used 4-fold higher antigen doses than we used in the IM group,
the anti-PA IgG ELISA titers and serum LeTx NT50 titers induced by nasal immunization
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may have been more like those induced by IM immunization. It is important to mention that
the human influenza vaccine study was performed without the use of adjuvants for either the
nasal or intramuscular routes of immunization[67]. While adjuvants and vaccine
formulations (i.e., bioadhesives) are expected to increase the immunogenicity and efficacy
of nasally-delivered vaccines, more work is needed to maximize the immunogenicity of
nasally-delivered vaccines to allow minimal antigen doses to induce the desired immune
response.
In conclusion, our results demonstrated that recombinant interleukin 1α and β provided
effective adjuvant activity for nasally-administered vaccines and supported the induction of
protective serum antibody responses. Studies in rabbits using varied anesthetic states
demonstrated that the anesthetic state influenced the immunogenicity of nasally-delivered
vaccines and suggested that the use of ketamine/xylazine anesthesia increased the retention
of the vaccine in the nasal cavity to provide maximal immunogenicity for the nasally-
delivered vaccine. Additional studies are required to develop nasal vaccine formulations that
provide the required immunogenicity without the need for anesthesia. Strategies that may
provide increased nasal retention include the use of bioadhesives and/or dry powder vaccine
formulations. Due to the difficulties and potential dangers associated with handling larger
animals such as non-human primates that are not sedated or anesthetized, studies to evaluate
the safety and efficacy of nasally-administered vaccines when delivered to awake hosts may
be performed in rabbits since the rabbit has nasal cavity lymphoid tissue similar to
humans[75] and can be safely handled without the use of anesthetics. Despite the usefulness
of the rabbit model for nasal immunization, human studies must be performed to optimize
nasal immunization strategies for use in humans.
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Figure 1. Intramuscular but not nasal delivery of IL-1β as a vaccine adjuvant induces increased
core body temperature in rabbits
NZW female rabbits were immunized with 100 μg tetanus toxoid combined with rhIL-1β as
adjuvant by the nasal or intramuscular route on day 0, 28 and 56. Rabbits were not sedated
or anesthetized for performance of the immunizations. Body temperature was monitored
immediately before (time 0) and at 2, 4, 6, 8 and 24 hours after immunization and
temperatures were compared within each vaccine group using ANOVA followed by
Dunnett’s test to compare the post-vaccination temperatures to the time 0 temperature. There
were three rabbits per adjuvant group and temperature readings from each day (day 0, 28
and 56) were combined. Rabbits immunized by the intramuscular route with TT + IL-1β at
312.5 ng/kg had significantly increased core body temperatures at 2 and 4 hours after
immunization (ANOVA, Dunnett’s test, p<0.05). Rabbits immunized with TT + IL-1β at
7,812.5 ng/kg had significantly increased core body temperatures at 2, 4, 6 and 8 hours after
immunization (ANOVA, Dunnett’s, p<0.05). All other comparisons within groups between
time 0 and post-vaccination body temperatures did not identify any significant change in
core body temperature (ANOVA, Dunnett’s test).
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Figure 2. Serum anti-TT IgG titers after nasal or intramuscular immunization with TT and
IL-1β in rabbits
Female NZW rabbits were immunized by the nasal or intramuscular route while awake with
100 μg tetanus toxoid combined with rhIL-1β on day 0, 28 and 56. Rabbits were not sedated
or anesthetized for performance of the immunizations. There were 3 rabbits in all groups.
Serum was collected on day 21, 49 and 77 and tested for the presence of anti-TT IgG by
ELISA (day 49 intranasal 7,812.5 ng/kg IL-1β and day 77 intranasal 12.5 ng/kg IL-1β had
only two rabbits/group due to the inability to collect blood from one rabbit). The horizontal
bars in each scatter plot represent the geometric mean titer (the solid bar for intramuscularly
immunized rabbits and the dashed bar for intranasally immunized rabbits). No statistical
comparisons were performed between groups due to the lack of power resulting from the
low numbers of animals per group. Undetectable serum antibody responses are outside the
range of the Y axis and are therefore not represented in the figure.
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Figure 3. Nasal immunization of rabbits induces variable antigen-specific IgG responses that are
significantly lower than IgG responses induced by intramuscular immunization
Female NZW rabbits (3 per group for each IL-1β adjuvant group) were immunized by the
nasal or intramuscular route while awake with 100 μg tetanus toxoid combined with rhIL-1β
(0.5, 12.5, 315.5 or 7812.5 ng/kg) on day 0, 28 and 56. Serum was collected on day 77 and
tested for the presence of anti-TT IgG by ELISA. The serum anti-TT IgG titer in nasally
immunized rabbits was 1:21,081 (geometric mean titer) while the serum anti-TT IgG titer in
intramuscularly immunized rabbits was 1:4,194,304 (geometric mean titer; p=0.0001 vs
nasal immunization, Mann Whitney).
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Figure 4. The state of anesthesia influences the efficacy of nasal immunization in rabbits
Female NZW rabbits were nasally immunized with 20 μg rPA combined with rhIL-1α (5–15
μg) on day 0, 21 and 42. There were 4 - 8 rabbits per group Control rabbits were immunized
intramuscularly with 10 μg rPA + alum on day 0, 21 and 42. Nasally immunized rabbits
were awake, sedated with acepromazine/butorphanol (sedated but upright and mobile in
their cage), sedated with acepromazine and anesthetized with isoflurane immediately before
immunization (sedated with anesthesia lasting less than 5 minutes after vaccination) or
anesthetized with ketamine/xylazine before immunization (deeply anesthetized for at least
30 minutes following nasal immunization). Serum was collected on day 42 and 56 and tested
for the presence of anti-PA IgG by ELISA. Serum anti-PA IgG were compared between
groups using a one way ANOVA and Tukey’s Multiple Comparison Test (PRISM). a. serum
anti-PA IgG titers significantly greater than in intranasally immunized awake rabbits,
p<0.05. b. serum anti-PA IgG titers significantly greater than in intranasally immunized
rabbits treated with acepromazine/butorphanol p<0.05. c. serum anti-PA IgG titers
significantly greater than in intranasally immunized rabbits treated with acepromazine/
isoflurane p<0.05. d. serum anti-PA IgG titers significantly greater than in intranasally
immunized rabbits treated with ketamine/xylazine p<0.05.
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Figure 5. Anesthetic state influences nasal retention in rabbits
Female NZW rabbits (3–4 per group) were used to monitor the nasal retention of non-
permeable Tc99m-sulfur colloid (Tc99m-SC) after delivery to nasal mucosal surfaces in
acepromazine/butorphanol-sedated, or ketamine/xylazine-anesthetized, rabbits. A. Typical
scintigraphy image of Tc99m-SC acquired from the lateral aspect immediately after delivery
with activity deposited within the nasal cavity (rabbit outline drawn for orientation purposes
only). B. Efficacy of delivery to rabbits. Total radioactivity delivered to rabbits at time zero
(includes nasal cavity, lungs, and swallowed activity within the digestive tract) as
percentage of expected delivery. No difference between groups; p=0.8571, Mann Whitney.
C. Efficacy of nasal cavity delivery. Radioactivity deposited regionally within the nasal
cavity as percentage of total activity administered to rabbits. No difference between groups;
p=0.6286, Mann Whitney. D. One of seven rabbits aspirated the Tc99m-sulfur colloid at the
time of delivery resulting in immediate accumulation of activity in the lungs and digestive
tract (the ketamine/xylazine-anesthetized rabbit with a low percentage of nasal cavity
delivery in Figure 5C). E. Retention of radioactivity initially deposited within nasal cavity.
Percent of delivered activity remaining in nasal cavity region of interest, compared between
groups at each time point using two-tailed unpaired Student’s T-test; *: p=0.0245. F. Nasal
retention: area under the retention versus time curve. The retention data of Figure 5E were
used to calculate the total area under the curve for the acepromazine/butorphanol and
ketamine/xylazine groups, respectively:* p =0.063 two-tailed unpaired Student’s T-test. G.
Typical scintigraphy image of Tc99m-sulfur colloid 180 minutes after delivery with regional
retention of radioactivity within the nasal cavity as well as clearance to the stomach.
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Table 3
Serum lethal toxin neutralizing antibody titers induced by nasal immunization are less
potent as compared to those induced by intramuscular immunization
Day 56 serum from rabbits nasally or intramuscularly immunized with rPA were tested for the presence of
anthrax lethal toxin neutralizing antibodies using a macrophage toxicity assay. Lethal toxin neutralizing titers
represent the titer calculated to neutralize 50% of the cell death induced by the lethal toxin. 50% neutralization
titers were compared by ANOVA followed by Tukey’s multiple comparison test.
Immunization Route Anesthesia Rabbit ID #
LeTx 50% Neutralizing








































neutralization 50% titers significantly greater than all nasal immunization groups.
B
neutralization titer significantly greater than in acepromazine + butorphanol treated rabbits.
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